JP2004536790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536790A5 JP2004536790A5 JP2002572997A JP2002572997A JP2004536790A5 JP 2004536790 A5 JP2004536790 A5 JP 2004536790A5 JP 2002572997 A JP2002572997 A JP 2002572997A JP 2002572997 A JP2002572997 A JP 2002572997A JP 2004536790 A5 JP2004536790 A5 JP 2004536790A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- components
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 6
- 230000001613 neoplastic Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 230000001225 therapeutic Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229960004679 Doxorubicin Drugs 0.000 claims 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 2
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims 2
- 229940086322 Navelbine Drugs 0.000 claims 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- -1 epidophyllotoxins Substances 0.000 claims 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- CILBMBUYJCWATM-IJDPFCGHSA-N vinorelbine L-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-IJDPFCGHSA-N 0.000 claims 2
- SXFWKZNLYYRHMK-UHFFFAOYSA-N 1H-indolo[7,6-f]quinoline Chemical class C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 claims 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 Daunorubicin Drugs 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 229960001842 Estramustine Drugs 0.000 claims 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 1
- 102100018758 IL3 Human genes 0.000 claims 1
- 108020001267 IL3 Proteins 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 241000863480 Vinca Species 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 241001135917 Vitellaria paradoxa Species 0.000 claims 1
- 229930013930 alkaloids Natural products 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000002195 synergetic Effects 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
Claims (19)
- 抗生物質がダウノルビシン、ドキソルビシン、ブレオマイシンおよびマイトマイシンから選択される、請求項1に記載の医薬組成物。
- 紡錘体阻害剤がビンカアルカロイド、それらの合成もしくは半合性類似体、エストラムスチンまたはナベルビンから選択される、請求項1に記載の医薬組成物。
- トポイソメラーゼ阻害剤がカンプトテシン、ならびにCPT−11、トポテカンおよびピリドベンゾインドール誘導体を包含するその誘導体から選択される、請求項1に記載の医薬組成物。
- 白金配位錯体がシスプラチンおよびカルボプラチンから選択される、請求項1に記載の医薬組成物。
- 造血系の成長因子をさらに含んでなる、請求項2〜5のいずれか一項に記載の医薬組成物。
- 投与が個別および同時である、請求項2〜5のいずれか一項に記載の組成物の成分の投与方法。
- 投与が個別および逐次である、請求項2〜5のいずれか一項に記載の組成物の成分の投与方法。
- 投与が個別および一定時間間隔である、請求項2〜5のいずれか一項に記載の組成物の成分の投与方法。
- その組成物の成分が同時投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
- 組成物の複数の成分が個別投与および同時投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
- 組成物の複数の成分が個別投与および半同時投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
- 組成物の複数の成分が個別投与および逐次投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
- 腫瘍性疾患が乳癌である、請求項10または11に記載の医薬組成物。
- 腫瘍性疾患が大腸癌である、請求項12または13に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/813,018 US6441026B1 (en) | 1993-11-08 | 2001-03-21 | Antitumor compositions containing taxane derivatives |
PCT/IB2002/000853 WO2002074289A2 (en) | 2001-03-21 | 2002-03-21 | Antitumor compositions containing taxane derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004536790A JP2004536790A (ja) | 2004-12-09 |
JP2004536790A5 true JP2004536790A5 (ja) | 2005-12-22 |
JP4467885B2 JP4467885B2 (ja) | 2010-05-26 |
Family
ID=25211230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002572997A Expired - Lifetime JP4467885B2 (ja) | 2001-03-21 | 2002-03-21 | タキサン誘導体を含有する抗腫瘍組成物 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6441026B1 (ja) |
EP (1) | EP1478355B1 (ja) |
JP (1) | JP4467885B2 (ja) |
CN (2) | CN1536995A (ja) |
AT (1) | ATE355837T1 (ja) |
AU (1) | AU2002244877B2 (ja) |
BR (1) | BR0208274A (ja) |
CA (1) | CA2440160C (ja) |
CY (1) | CY1106582T1 (ja) |
DE (1) | DE60218751T2 (ja) |
DK (1) | DK1478355T3 (ja) |
EA (1) | EA006878B1 (ja) |
ES (1) | ES2282400T3 (ja) |
HU (1) | HUP0500478A2 (ja) |
IL (1) | IL157992A (ja) |
MX (1) | MXPA03008539A (ja) |
PT (1) | PT1478355E (ja) |
SI (1) | SI1478355T1 (ja) |
WO (2) | WO2002074232A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
BRPI0207961B8 (pt) * | 2001-03-14 | 2021-05-25 | Bristol Myers Squibb Co | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. |
ITRM20020191A1 (it) * | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
NZ535992A (en) * | 2002-05-17 | 2008-11-28 | Aventis Pharma Sa | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
WO2004035034A2 (en) * | 2002-10-16 | 2004-04-29 | Ilex Products, Inc. | Clofarabine and taxane chemotherapy combination |
ITMI20030317A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale. |
WO2004103344A1 (en) * | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
CN100340296C (zh) * | 2005-02-03 | 2007-10-03 | 山东蓝金生物工程有限公司 | 一种抗癌体内植入剂 |
DK3248600T3 (da) * | 2005-02-18 | 2020-07-06 | Abraxis Bioscience Llc | Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
DK2206736T3 (da) * | 2005-12-05 | 2012-04-23 | Nitto Denko Corp | Polyglutamat-aminosyre-konjugater og fremgangsmåder |
EP1913958B1 (en) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
WO2008124735A2 (en) * | 2007-04-10 | 2008-10-16 | Nitto Denko Corporation | Multi-functional polyglutamate drug carriers |
ES2430380T3 (es) | 2007-05-09 | 2013-11-20 | Nitto Denko Corporation | Composiciones que incluyen un compuesto hidrófobo y un conjugado de poliaminoácido |
DK2155254T3 (da) * | 2007-05-09 | 2013-03-04 | Nitto Denko Corp | Med platinlægemidler konjugerede polymere |
CN101707869A (zh) * | 2007-05-09 | 2010-05-12 | 日东电工株式会社 | 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物 |
MX2010009670A (es) * | 2008-03-06 | 2010-09-22 | Nitto Denko Corp | Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer. |
CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
SG10201906075VA (en) | 2010-03-29 | 2019-08-27 | Abraxis Bioscience Llc | Methods of treating cancer |
WO2011153010A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Biosciences, Llc | Methods of treatment of pancreatic cancer |
AU2011325982C1 (en) * | 2010-11-12 | 2015-08-20 | Endocyte, Inc. | Methods of treating cancer |
CN102241648B (zh) * | 2011-01-31 | 2016-08-03 | 沈阳东星医药科技有限公司 | 抗多药耐药紫杉烷类衍生物及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
US4876399A (en) | 1987-11-02 | 1989-10-24 | Research Corporation Technologies, Inc. | Taxols, their preparation and intermediates thereof |
US5136060A (en) | 1989-11-14 | 1992-08-04 | Florida State University | Method for preparation of taxol using an oxazinone |
US5015744A (en) | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5645988A (en) | 1991-05-08 | 1997-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of identifying drugs with selective effects against cancer cells |
AU2005692A (en) | 1991-05-08 | 1992-12-21 | United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer |
US5229526A (en) | 1991-09-23 | 1993-07-20 | Florida State University | Metal alkoxides |
US5284864A (en) | 1991-09-23 | 1994-02-08 | Florida State University | Butenyl substituted taxanes and pharmaceutical compositions containing them |
US5262409A (en) | 1991-10-11 | 1993-11-16 | Fred Hutchinson Cancer Research Center | Binary tumor therapy |
US5294737A (en) | 1992-02-27 | 1994-03-15 | The Research Foundation State University Of New York | Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
EP0982028A1 (en) * | 1998-08-20 | 2000-03-01 | Aventis Pharma S.A. | New use of taxoid derivatives |
-
2001
- 2001-03-21 US US09/813,018 patent/US6441026B1/en not_active Expired - Fee Related
-
2002
- 2002-03-21 PT PT02713093T patent/PT1478355E/pt unknown
- 2002-03-21 SI SI200230525T patent/SI1478355T1/sl unknown
- 2002-03-21 EP EP02713093A patent/EP1478355B1/en not_active Expired - Lifetime
- 2002-03-21 DK DK02713093T patent/DK1478355T3/da active
- 2002-03-21 DE DE60218751T patent/DE60218751T2/de not_active Expired - Lifetime
- 2002-03-21 WO PCT/IB2002/002239 patent/WO2002074232A2/en not_active Application Discontinuation
- 2002-03-21 ES ES02713093T patent/ES2282400T3/es not_active Expired - Lifetime
- 2002-03-21 CN CNA028068572A patent/CN1536995A/zh active Pending
- 2002-03-21 CN CNA2009101299448A patent/CN101590057A/zh active Pending
- 2002-03-21 HU HU0500478A patent/HUP0500478A2/hu unknown
- 2002-03-21 WO PCT/IB2002/000853 patent/WO2002074289A2/en active IP Right Grant
- 2002-03-21 EA EA200301047A patent/EA006878B1/ru not_active IP Right Cessation
- 2002-03-21 AU AU2002244877A patent/AU2002244877B2/en not_active Ceased
- 2002-03-21 BR BR0208274-8A patent/BR0208274A/pt not_active IP Right Cessation
- 2002-03-21 AT AT02713093T patent/ATE355837T1/de active
- 2002-03-21 JP JP2002572997A patent/JP4467885B2/ja not_active Expired - Lifetime
- 2002-03-21 MX MXPA03008539A patent/MXPA03008539A/es active IP Right Grant
- 2002-03-21 CA CA2440160A patent/CA2440160C/en not_active Expired - Lifetime
-
2003
- 2003-09-18 IL IL157992A patent/IL157992A/en not_active IP Right Cessation
-
2007
- 2007-05-10 CY CY20071100643T patent/CY1106582T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004536790A5 (ja) | ||
KR100334051B1 (ko) | 탁산유도체를함유하는항종양조성물 | |
ES2282400T3 (es) | Composiciones antitumorales que contienen derivados de taxano. | |
JP5579715B2 (ja) | cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
EP1827437B1 (en) | Combinations of therapeutic agents for treating cancer | |
AU758191B2 (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
JP5235304B2 (ja) | 抗癌療法 | |
Kudelka et al. | An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix | |
EP1261374A2 (en) | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents | |
Sternberg | Satraplatin in the treatment of hormone-refractory prostate cancer. | |
JP2007511509A (ja) | Et−743およびパクリタキセルの使用を含むガンの併用療法 | |
US20100240595A1 (en) | Improved Antitumoral Treatments | |
RU2005132175A (ru) | Комбинированное лечение опухолей, включающее неморубицин и лучевую терапию | |
AU774393B2 (en) | Anti-tumor synergetic composition | |
EP2344156A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent | |
Hanauske | Recent advances in anticancer drug development |